Riding on positive data, argenx raises $1.1B while Alzheimer's biotech Acumen lands $130M
An immunology player and an Alzheimer’s biotech each have a big boost in cash — a massive $1.1 billion for argenx and $130 million for Acumen …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
